UroGen Pharma (URGN) Cost of Revenue (2017 - 2026)
UroGen Pharma's (URGN) quarterly Cost of Revenue came in at $4.1 million in Q1 2026, up 77.64% YoY from $2.3 million in Q1 2025, and up 25.84% on a QoQ basis from $3.3 million in Q4 2025.
UroGen Pharma (URGN) Cost of Revenue (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 9 years of Cost of Revenue data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Cost of Revenue rose 77.64% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 50.33% YoY) and the FY2025 annual result came in at $12.4 million, up 40.15% from the prior year.
- Cost of Revenue advanced to $4.1 million in Q1 2026, from $3.3 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $4.1 million in Q1 2026 to a low of $1.5 million in Q1 2022.
- A 5-year average of $2.5 million and a median of $2.3 million in 2025 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2024 — Cost of Revenue fell 23.71% — and 2026, when it surged 77.64%.
- Tracing URGN's Cost of Revenue over 5 years: stood at $2.3 million in 2022, then gained by 1.02% to $2.3 million in 2023, then advanced by 8.09% to $2.5 million in 2024, then jumped by 33.1% to $3.3 million in 2025, then advanced by 25.84% to $4.1 million in 2026.
- The last three Cost of Revenue figures came in at $4.1 million (Q1 2026), $3.3 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.57 Mn |
| Jun 30, 2026 | 6.57 Mn |
| Mar 31, 2026 | 4.14 Mn |
| Mar 31, 2026 | 4.14 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 3.28 Mn |
| Sep 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 3.55 Mn |
| Jun 30, 2025 | 3.55 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | 2.23 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |